M&A Deal Summary |
|
|---|---|
| Date | 2016-11-01 |
| Target | Kolltan Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Celldex Therapeutics |
| Deal Type | Add-on Acquisition |
| Deal Value | 63M USD |
| Advisor(s) | Guggenheim Securities (Financial) Holland & Knight (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1983 |
| Sector | Life Science |
| Employees | 148 |
| Revenue | 7M USD (2024) |
Celldex Therapeutics is an integrated bio pharmaceutical company that applies its comprehensive precision targeted immunotherapy platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex Therapeutics was founded in 1983 and is based in Hampton, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Connecticut M&A | 2 of 2 |
| Country: United States M&A | 3 of 3 |
| Year: 2016 M&A | 1 of 1 |
| Size (of disclosed) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-03-29 |
CuraGen
Branford, Connecticut, United States CuraGen has a portfolio of 11 fully-owned, human antibodies that the Company selected, optimized and advanced during its collaboration with Abgenix (acquired by Amgen). CR011, currently in Phase 2 studies, is an antibody-drug conjugate that targets GPNMB, a protein that is highly expressed in metastatic breast cancer and melanoma. CR011 has shown promising early evidence of anti-tumor activity, including objective tumor responses, in patients with breast cancer and unresectable stage III and IV melanoma. |
Buy | $95M |
